Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RELATLIMAB vs REPOTRECTINIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RELATLIMAB vs REPOTRECTINIB: Safety Overview

Metric RELATLIMAB REPOTRECTINIB
Total FAERS Reports 177 187
Deaths Reported 29 27
Death Rate 16.4% 14.4%
Hospitalizations 145 48
Average Patient Age 64.5 yrs 60.8 yrs
% Female Patients 34.6% 61.1%
FDA Approval Date N/A Jun 11, 2024
Manufacturer N/A E.R. Squibb & Sons, L.L.C.
Route N/A ORAL
Marketing Status N/A Prescription